Circular RNA hsa_circ_0003823 promotes the Tumor Progression, Metastasis and Apatinib Resistance of Esophageal Squamous Cell Carcinoma by miR-607/CRISP3 Axis

Wang, Yuming; Zhao, Qi-Wu; Sun, Zhuo; Lin, Haiping; Xu, Xin; Cao, Min; Fu, Yujie; Zhao, Xiaojing; Ma, Xiumei; Ye, Qing

doi:10.7150/ijbs.76096

Cited by 16 publications

(8 citation statements)

References 56 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The experiment was conducted thrice to establish reproducibility. The primer sequences, as previously reported, are displayed in Table S1 ( Wang et al, 2022 ).…”

Section: Methodsmentioning

confidence: 99%

See 1 more Smart Citation

Exploring the role of differentially expressed metabolic genes and their mechanisms in bone metastatic prostate cancer

Zhang

Zhao

et al. 2023

PeerJ

View full text Add to dashboard Cite

Background Approximately 10–20% of patients diagnosed with prostate cancer (PCa) evolve into castration-resistant prostate cancer (CRPC), while nearly 90% of patients with metastatic CRPC (mCRPC) exhibit osseous metastases (BM). These BM are intimately correlated with the stability of the tumour microenvironment. Purpose This study aspires to uncover the metabolism-related genes and the underlying mechanisms responsible for bone metastatic prostate cancer (BMPCa). Methods Gene Expression Omnibus (GEO) and The Cancer Genome Atlas (TCGA) datasets of PCa and BM were analyzed through R Studio software to identify differentially expressed genes (DEGs). The DEGs underwent functional enrichment via Kyoto Encyclopedia of Genes and Genomes (KEGG) and Gene Ontology (GO), with key factors screened by a random forest utilized to establish a prognostic model for PCa. The study explored the relationship between DEGs and the stability of the immune microenvironment. The action and specificity of CRISP3 in PCa was validated through western blot analysis, CCK-8 assay, scratch assay, and cellular assay. Results The screening of GEO and TCGA datasets resulted in the identification of 199 co-differential genes. Three DEGs, including DES, HBB, and SLPI, were selected by random forest classification model and cox regression model. Immuno-infiltration analysis disclosed that a higher infiltration of naïve B cells and resting CD4 memory T cells occurred in the high-expression group of DES, whereas infiltration of resting M1 macrophages and NK cells was greater in the low-expression group of DES. A significant infiltration of neutrophils was observed in the high-expression group of HBB, while greater infiltration of gamma delta T cells and M1 macrophages was noted in the low-expression group of HBB. Resting dendritic cells, CD8 T cells, and resting T regulatory cells (Tregs) infiltrated significantly in the high-expression group of SLPI, while only resting mast cells infiltrated significantly in the low-expression group of SLPI. CRISP3 was established as a critical gene in BMPCa linked to DES expression. Targeting CRISP3, d-glucopyranose may impact tumour prognosis. During the mechanistic experiments, it was established that CRISP3 can advance the proliferation and metastatic potential of PCa by advancing epithelial-to-mesenchymal transition (EMT). Conclusion By modulating lipid metabolism and maintaining immunological and microenvironmental balance, DES, HBB, and SLPI suppress prostate cancer cell growth. The presence of DES-associated CRISP3 is a harbinger of unfavorable outcomes in prostate cancer and may escalate tumor proliferation and metastatic capabilities by inducing epithelial-mesenchymal transition.

show abstract

“…The experiment was conducted thrice to establish reproducibility. The primer sequences, as previously reported, are displayed in Table S1 ( Wang et al, 2022 ).…”

Section: Methodsmentioning

confidence: 99%

“…Glyceraldehyde 3-phosphate dehydrogenase (GAPDH) was utilized as an internal standard. The primer sequences, as previously reported, are displayed in Table S2 ( Wang et al, 2022 ).…”

Section: Methodsmentioning

confidence: 99%

Exploring the role of differentially expressed metabolic genes and their mechanisms in bone metastatic prostate cancer

Zhang

Zhao

et al. 2023

PeerJ

View full text Add to dashboard Cite

show abstract

“…In breast cancer, circRNA expression profiles may distinguish between estrogen receptor-positive, HER2-positive, and triple-negative breast cancer [ 166 ]. In tissue samples, the upregulation of hsa_circ_0003823, circPUM1, circCYP24A1, and circCNOT6L presented diagnostic performance with considerable sensitivity and specificity values, which exhibited relatively higher recurrence of esophageal squamous cell carcinoma (ESCC) [ 167 – 170 ]. In the plasma samples, Hu et al, found that highly concentration of plasma circGSK3β and CEA can indicate the recurrence/metastasis of ESCC [ 171 ].…”

Section: Characterization Of Circrnasmentioning

confidence: 99%

New insight into circRNAs: characterization, strategies, and biomedical applications

Feng,

Zhu,

et al. 2023

Exp Hematol Oncol

View full text Add to dashboard Cite

Circular RNAs (circRNAs) are a class of covalently closed, endogenous ncRNAs. Most circRNAs are derived from exonic or intronic sequences by precursor RNA back-splicing. Advanced high-throughput RNA sequencing and experimental technologies have enabled the extensive identification and characterization of circRNAs, such as novel types of biogenesis, tissue-specific and cell-specific expression patterns, epigenetic regulation, translation potential, localization and metabolism. Increasing evidence has revealed that circRNAs participate in diverse cellular processes, and their dysregulation is involved in the pathogenesis of various diseases, particularly cancer. In this review, we systematically discuss the characterization of circRNAs, databases, challenges for circRNA discovery, new insight into strategies used in circRNA studies and biomedical applications. Although recent studies have advanced the understanding of circRNAs, advanced knowledge and approaches for circRNA annotation, functional characterization and biomedical applications are continuously needed to provide new insights into circRNAs. The emergence of circRNA-based protein translation strategy will be a promising direction in the field of biomedicine.

show abstract

“…With the development of RNA sequencing and microarray technology, circRNAs have gradually been recognized as important tumour biomarkers and present evident regulatory role in various types of cancers 7,9–12 . In addition, with the help of advanced detection technologies, multiple miRNA binding sites on circRNAs were detected, which can play a role in regulating protein expression by binding to each other, and abnormally expressed circRNAs can act as miRNA sponges and participate in cancer‐related signalling pathways, thus affecting the progression of squamous carcinoma in patients 13,14 . However, the role of circRNA as well as its molecular mechanism in OSCC tissues is largely unknown.…”

Section: Introductionmentioning

confidence: 99%

“…7,[9][10][11][12] In addition, with the help of advanced detection technologies, multiple miRNA binding sites on circRNAs were detected, which can play a role in regulating protein expression by binding to each other, and abnormally expressed circRNAs can act as miRNA sponges and participate in cancer-related signalling pathways, thus affecting the progression of squamous carcinoma in patients. 13,14 However, the role of circRNA as well as its molecular mechanism in OSCC tissues is largely unknown. Smad4, a central signalling component of transforming growth factor β (TGFβ), is a multifunctional cytokine that regulates cell growth and differentiation.…”

mentioning

confidence: 99%

CircLDLRAD3 inhibits Oral squamous cell carcinoma progression by regulating miR‐558/Smad4/TGF‐β

Zhang

Guo

Liu

et al. 2023

J Cellular Molecular Medi

View full text Add to dashboard Cite

Oral squamous cell carcinoma (OSCC) is a malignant neoplasm with high mortality and morbidity. The role of circRNA and its molecular mechanism in OSCC remains largely unknown. The study aims to explore the role of a novel circular RNA (circLDLRAD3) in OSCC and its underlying mechanism. PCR and fluorescence in situ hybridization were used to explore the expression features of circLDLRAD3 in OSCC. The effects of circLDLRAD3 on the behaviour of OSCC were investigated using CCK‐8, colony formation assay, transwell and animal experiments. Bioinformatics analysis along with dual luciferase reporter assay and RIP assay were used to reveal the interaction between circLDLRAD3, miR‐558 and Smad4. It was revealed that circLDLRAD3 exhibited low expression status in OSCC. CircLDLRAD3 inhibits proliferation, migration, and invasion of OSCC cells both in vitro and in vivo. Mechanistically, circLDLRAD3 could bind with miR‐558 to positively regulate its target gene Smad4 expression. Rescue experiments further confirmed both miR‐558 overexpression and Smad4 knockdown could reverse the influence of circLDLRAD3 on OSCC phenotypes. Moreover, circLDLRAD3 regulate the TGF‐β signalling pathways to influence EMT through miR‐558/Smad4 axis. Our study found that circLDLRAD3 is downregulated in OSCC and verified its tumour suppressor function and mechanism in OSCC through sponging miR‐558 to regulate miR‐558/Smad4/TGF‐β axis. The characterization of such regulating network uncovers an important mechanism underlying OSCC progression, which could provide promising targets targeted therapy strategies for OSCC in the future.

show abstract

Circular RNA hsa_circ_0003823 promotes the Tumor Progression, Metastasis and Apatinib Resistance of Esophageal Squamous Cell Carcinoma by miR-607/CRISP3 Axis

Cited by 16 publications

References 56 publications

Exploring the role of differentially expressed metabolic genes and their mechanisms in bone metastatic prostate cancer

Exploring the role of differentially expressed metabolic genes and their mechanisms in bone metastatic prostate cancer

New insight into circRNAs: characterization, strategies, and biomedical applications

CircLDLRAD3 inhibits Oral squamous cell carcinoma progression by regulating miR‐558/Smad4/TGF‐β

Contact Info

Product

Resources

About